Drugs / BI 765049
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06882746 | Mar 2025 → Sep 2026 | colorectal carcinoma, gastric carcinoma, pancreatic ductal adenocarcinoma | Boehringer Ingelheim | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT06091930 | Feb 2024 → Aug 2025 | colorectal cancer, head and neck cancer, liver cancer, lung cancer +1 | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04752215 | May 2021 → Nov 2024 | cancer | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 765049 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06882746 ↗ |
| Route | Intravenous | “During this time, they get BI 765049 alone or in combination with ezabenlimab as infusion into a vein every 3 weeks.” NCT04752215 ↗ |